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serving RRF will reduce the severity of LVH, improve cardiacA novel association between residual renal function and left
performance and hence survival of these patients.ventricular hypertrophy in peritoneal dialysis patients.
Background. Left ventricular hypertrophy (LVH) and dial-
ysis adequacy are both important predictors for mortality in di-
alysis patients. This study evaluated the association between
Cardiovascular disease is a major cause of death in di-residual renal function (RRF) and the severity of LVH in end-
alysis patients, accounting over 40% of the mortality [1]stage renal failure (ESRF) patients undergoing long-term con-
tinuous ambulatory peritoneal dialysis (CAPD). and is considerably higher than that of the general popu-
Methods. A cross-section study was performed with left ven- lation [2]. The Framingham study showed that the pres-
tricular mass index (LVMi), determined in 158 non-diabetic ence of left ventricular hypertrophy (LVH) is associatedCAPD patients using echocardiography and its relationship
with increased mortality [3]. Cross-section surveys notedwith residual glomerular filtration rate (GFR), peritoneal dial-
up to 80% of the dialysis patients have an abnormalysis (PD) and total weekly urea clearance (Kt/V) and other
known risk factors for LVH was evaluated. echocardiogram, among which LVH is the most frequent
Results. Twelve patients had no LVH (group I). The re- finding [4], and its presence has been confirmed to be an
maining 146 patients were stratified [group II (lowest), III and important independent determinant of survival in theseIV (highest)] according to the LVMi (median 207 g/m2; range
patients [5–7].103 to 512 g/m2). Across the four groups of patients with in-
Advanced age, hypertension, chronic anemia, hypoal-creasing LVMi, there was significant decline in GFR (2.27 
1.98 vs. 1.49  1.58 vs. 1.61  1.91 vs. 0.80  1.42 mL/min/ buminemia and time on dialysis have been suggested to
1.73 m2; P  0.011) and total weekly Kt/V (1.98  0.44 vs. be some of the strongest risk factors for LVH in dialysis
1.96 0.38 vs. 1.92 0.42 vs. 1.71 0.42; P 0.037); however, patients [8–11]. In pre-dialysis patients, the decline inPD Kt/V was similar for all four groups. Patients with better-
creatinine clearance was associated with an increase inpreserved residual GFR not only had significantly higher total
the LVM index (LVMi) [12]. Regression of LVH wasKt/V, but were less anemic and hypoalbuminemic and had a
trend toward lower systolic blood pressure and arterial pulse noted in dialysis patients after a successful kidney trans-
pressure. Multiple regression analysis showed that other than plant [13]. Both of these observations suggest that the
age, gender, body weight, arterial pulse pressure, hemoglobin presence of residual renal function (RRF) and the degreeand serum albumin, known factors for LVH, residual GFR (es-
of uremia may be important in determining the LVMi.timated mean7.94; 95% confidence interval15.13 to0.74;
This study was therefore performed to determine theP  0.031) was also independently associated with LVMi.
Conclusions. Other than anemia, hypoalbuminemia and ar- association, if any, between the degree of RRF and the
terial pulse pressure, this study demonstrates an important, LVMi of end-stage renal failure (ESRF) patients under-
novel association between the degree of RRF and severity of going long-term continuous ambulatory peritoneal dial-LVH in ESRF patients undergoing long-term CAPD. Prospec-
ysis (CAPD).tive studies are needed to define if indeed there is a cause-effect
relationship between this association, to evaluate if a decline
in residual GFR is independently associated with an increase
METHODSin LVMi, and to determine whether treatment directed at pre-
Patients
This study was performed in 158 non-diabetic ChineseKey words: glomerular filtration rate, cardiac mass, uremia, end-stage
renal failure, CAPD, cardiovascular disease, dialysis. ESRF patients who had been on maintenance CAPD
for at least six months at the Prince of Wales HospitalReceived for publication November 13, 2001
in Hong Kong. Other than excluding patients with con-and in revised form February 6, 2002
Accepted for publication March 12, 2002 genital or valvular heart disease, patients with underlying
active inflammatory disease such as systemic lupus ery- 2002 by the International Society of Nephrology
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thematosus and malignancy, all non-diabetic CAPD pa- number of antihypertensive medications was averaged
for the 12 months preceding the echocardiography.tients were included into the study. Among the 158 pa-
Serum biochemical parameters including hemoglobintients, a history of heart failure was noted in 46 patients
and albumin measured at every six- to eight-week inter-(29%). The study protocol was approved by the Human
val were averaged for the 12 months preceding the echo-Research Ethics Committee of the Chinese University
cardiography in order to obtain a mean value for eachof Hong Kong. Informed consent was obtained from all
parameter. Serum albumin was measured using the brom-patients before the study.
cresol purple method.
Echocardiography
Statistical analysisEchocardiography was performed using a GE-Ving-
Statistical analysis was performed using SPSS soft-Med System V echocardiographic machine (GE-VingMed
ware, version 10.0 (SPSS, Inc., Chicago, IL, USA). Re-Sound AB, Horten, Norway) and a 3.5 mHz multiphase-
sults were expressed as mean  SD. Categorical dataarray probe in patients lying in the left lateral decubitus
were compared between groups by the chi-square test.position, by a single experienced cardiologist blinded to
Continuous data were compared using analysis of vari-all clinical details of patients. All echocardiographic data
ance (ANOVA). Significance for trend effect was testedwas recorded according to the guidelines of the Ameri-
across the four groups of patients with increasing LVMican Society of Echocardiography [14, 15]. Left ventricu-
and also across the three groups of patients with increas-lar mass was corrected by the body surface area and ex-
ing residual GFR. Factors for LVMi with a P value0.25pressed as LVMi, an index reflecting the severity of
were further selected into the multiple regression modelLVH. LVH was defined as LVMi 131 g/m2 in men and
with both LVMi and GFR entered into the model as100 g/m2 in women in accordance with Framingham
continuous variables. A backward stepwise procedure wascriteria [16].
performed with a P value0.05 to remove and to identify
factors significantly associated with LVMi in our dialy-Assessment of residual renal function and indices of
sis patients, and diagnostic testing for multi-colinearitydialysis adequacy
was performed. Spearman correlation also was performedResidual glomerular filtration rate (GFR) was calcu-
to evaluate the correlations between GFR and hemoglo-lated as an average of the 24-hour urine urea and creati-
bin, serum albumin, systolic and diastolic blood pressuresnine clearance (CCr) [17]. Adequacy of dialysis was deter- as well as arterial pulse pressure. All P values were two-mined by measurement of total weekly urea clearance
sided and significance was taken at the 5% level.(Kt/V) and CCr using standard methods [18]. Creatinine
concentration in dialysate was corrected for interference
by glucose according to reference formula determined RESULTS
in our laboratory [19]. The contribution of PD and renal Clinical characteristics of the 158 non-diabetic CAPD
component to the total Kt/V also was estimated sepa- patients are shown in Table 1. Daily PD exchanges were
rately. Total body water was derived using the Watson 4.5 L in 4 patients, 5 L in 1 patient, 6 L in 112 patients,
formula [20], with the actual body weight determined by 8 L in 37 patients and 10 L in 4 patients. The average
a weighing scale after patients had their abdomen LVMi of our patients was 221 (range 79 to 512) g/m2
drained dry of peritoneal fluid. Residual GFR and indi- and was slightly higher in men (232 96 vs. 202 79 g/m2;
ces of dialysis adequacy measured every six-months were P  0.110) than women. Twelve patients had normal
averaged for the 12 months preceding echocardiography. LVMi (group I). One hundred and forty-six (equal male
to female ratio) patients (92%) had LVH according to
Data collection the criteria. Patients with LVH were further divided ac-
Demographic data including age, sex, duration on dial- cording to their LVMi: group II (N  48), those with
ysis, cause of renal failure and smoking history were LVMi 183.33 g/m2; group III (N  49), those between
collected. Systolic and diastolic blood pressure values 183.33 and 249.29 g/m2; and IV (N  49), those between
measured at every follow-up visit at six- to eight-week 249.30 and 512 g/m2.
intervals were averaged for the 12 months preceding Clinical characteristics of the four groups of patients
echocardiography. Use of erythropoietin (EPO) and are shown in Table 2. Patients’ age, systolic blood pres-
antihypertensive medication including angiotensin-con- sure, arterial pulse pressure as well as the percentage of
verting enzyme inhibitors (ACEI), calcium channel patients with positive smoking history showed a signifi-
blockers and beta blockers were recorded on every fol- cant trend effect across the four groups of patients with
low-up visit at the six- to eight-week intervals. Total increasing LVMi. No difference was noted in the diastolic
cumulated EPO dosage received for the 12 months pre- blood pressure among the four groups. A trend toward
a greater number of antihypertensive medication andceding the echocardiography was calculated. The total
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Table 1. Characteristics of the study population having a lower requirement for EPO. A trend toward
lower systolic blood pressure and arterial pulse pressureTotal (N  158)
was also observed. Serum albumin also was reduced sig-Age years 5313
Male sex N (%) 88 (50) nificantly across patients with declining residual GFR
Smoker/ex-smoker N (%) 56 (35) (Table 4). Residual GFR was significantly and positively
Renal diagnosis N (%)
correlated with hemoglobin (r  0.317, P  0.001) andGlomerulonephritis 69 (44)
Hypertensive nephrosclerosis 27 (17) serum albumin (r  0.227, P  0.004), but negatively
Polycystic disease 12 (8) correlated with arterial pulse pressure (r  0.216, P 
Obstructive uropathy 9 (6)
0.006). GFR was only weakly correlated with systolicTubulointerstitial disease 6 (4)
Unknown 35 (22) (r  0.184, P  0.021) and was not correlated at all
Duration of CAPD months 4231 with diastolic blood pressure (r  0.022, P  0.782).
Body weight kg 5710
Multiple regression analysis showed that body weight,Body height m 1.580.08
Systolic blood pressure mm Hg 14717 arterial pulse pressure, hemoglobin, serum albumin, and
Diastolic blood pressure mm Hg 8410 residual GFR were independent factors associated with
Number of antihypertensives 1.61.0
LVMi, which explained 31% of the total variation inOn beta blocker N (%) 91 (58)
On calcium channel blocker N (%) 97 (61) LVMi (Table 5). There was no multi-colinearity between
On converting enzyme inhibitor N (%) 38 (24) residual GFR, serum albumin, hemoglobin and arterial
Hemoglobin g/dL 9.441.59
pulse pressure.On erythropoietin N (%) 68 (43)
Serum albumin g/L 294 The association between RRF and other echocardio-
Total weekly urea clearance 1.870.42 graphic parameters was also evaluated (Table 6). Pa-
Residual glomerular filtration rate mL/min/1.73 m2 1.371.72
tients with better-preserved RRF not only had signifi-
Continuous values are expressed as mean  SD. cantly lower LVMi, but also less LV wall and septal
thickening, smaller LV systolic diameter, and a trend
toward a smaller LV diastolic diameter. LV ejection
greater use of ACEI was observed across the four groups fraction and fractional shortening also were significantly
of patients with increasing LVMi, although this did not higher among patients with a greater degree of RRF,
reach statistical significance. indicating that the presence of a better-preserved RRF
There were significantly more patients receiving EPO, was associated with less LVH, LV dilation and better
yet an increasing severity of anemia across the four LV function.
groups with increasing LVMi. The total cumulative EPO
dose received for the 12 months preceding echocardiog-
DISCUSSIONraphy, on the contrary, was higher among patients with
The Stoke Peritoneal Dialysis Study [21, 22] and thegreater LVMi, indicating that resistance to EPO’s action
CANUSA study [23, 24] previously confirmed the impor-was associated with a greater increase in LVMi. Serum
tance of urea clearance and nutrition status in predictingalbumin declined significantly across the four groups
the survival of dialysis patients. On the other hand, car-(Table 3).
diovascular disease accounts for over 40% of the totalGroup IV patients were performing the highest vol-
mortality in dialysis patient [1], with LVH being one ofume of PD exchanges compared to all other groups.
the major determinants of survival [5–7]. Yet, the exactHowever, despite having a higher daily PD exchange
link between urea clearance and LVH has never beenvolume, the total weekly Kt/V and CCr were reduced sig-
explored. To our knowledge this is the first study thatnificantly across the four groups and was contributed by
describes an important and novel association betweenthe significant decline in residual GFR across the four
the degree of RRF and severity of LVH in long-termgroups. No difference was noted in the PD Kt/V among
CAPD patients. The greater was the degree of RRF, thethe four groups (Table 3). Indeed, total weekly Kt/V
less severe was the LVH, LV dilation, and the betterand CCr were significantly higher among patients with
was the LV systolic function. RRF has a major contribu-better-preserved RRF despite having lower daily PD
tion to the delivery of adequate dialysis [25–27]. Loss ofexchanges and lower PD Kt/V values (Table 4). A sig-
RRF with the increasing duration of dialysis is not onlynificant decreasing trend was noted in the LVMi of pa-
associated with a worse nutritional status, but also atients with increasing Kt/V values (P  0.002) and pa-
higher mortality [22]. It is well recognized that the contri-tients with increasing residual GFR (257  96 vs. 221 
bution of RRF and PD Kt/V to the overall nutritional86 vs. 198  60 vs. 189  74 vs. 184  64 g/m2; P 
status is not equivalent in that with total Kt/V being0.001; Fig. 1). No difference, however, was noted in the
equal, those with RRF have significantly higher serumLVMi among patients with increasing PD Kt/V (Fig. 1).
albumin level than those with no RRF [28]. Our resultsOther than having a higher Kt/V, patients with better-
preserved RRF were significantly less anemic despite showed that the relationship between RRF, PD Kt/V
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Table 2. Clinical characteristics of the four groups of patients with increasing left ventricular mass index
Left ventricular mass index in tertiles
I (No LVH) II (Lowest) III (Middle) IV (Highest) P value
(N  12) (N  48) (N  49) (N  49) for trenda
Male sex N (%) 9 (75) 16 (33) 24 (49) 30 (61) 0.209
Age years 499 5213 5512 5612 0.037
On dialysis months 3923 3631 3934 4931 0.287
Renal diagnosis N (%)
Glomerulonephritis 5 (42) 23 (48) 18 (37) 23 (47) 0.709
Hypertensive nephrosclerosis 2 (17) 6 (13) 13 (27) 6 (12)
Polycystic kidney disease 1 (8) 5 (10) 5 (10) 1 (2)
Obstructive uropathy 0 (0) 3 (6) 2 (4) 4 (8)
Tubulointerstitial nephritis 0 (0) 2 (4) 3 (6) 1 (2)
Unknown 4 (33) 8 (17) 8 (16) 14 (19)
Current/ex-smoker N (%) 3 (27) 12 (25) 15 (31) 25 (51) 0.011
Body weight kg 5511 5410 559 6010 0.062
Body height m 1.620.07 1.560.08 1.570.07 1.600.08 0.458
Systolic blood pressure mm Hg 13712 14116 14917 15318 0.001
Diastolic blood pressure mm Hg 857 839 8510 8510 0.980
Pulse pressure mm Hg 529 5712 6413 6813 0.001
Number of antihypertensives 1.30.9 1.51.0 1.60.9 1.81.0 0.088
On beta blocker N (%) 7 (58) 27 (56) 25 (51) 32 (65) 0.472
On calcium channel blocker N (%) 7 (58) 29 (60) 32 (65) 29 (59) 0.992
On converting enzyme inhibitor N (%) 1 (8) 10 (21) 13 (27) 14 (29) 0.140
Continuous values are expressed as mean  SD.
a Significance for trend effect was tested across the four groups of patients
Table 3. Biochemical and dialytic parameters of the four groups of patients with increasing left ventricular mass index
Left ventricular mass index in tertiles
P value
I (normal) II (lowest) III (middle) IV (highest) for trenda
Hemoglobin g/dL 10.92.3 9.71.6 9.51.5 8.91.3 0.001
On EPO N (%) 2 (17) 19 (40) 17 (35) 30 (61) 0.004
Cumulative 12-month EPO dose, 10 3 U 3275 5173 5778 9085 0.022
Serum albumin g/L 313 304 294 285 0.004
Daily PD exchanges L/day 6.31.2 6.30.8 6.20.8 7.11.4 0.014
Total weekly Kt/V 1.980.44 1.960.38 1.920.42 1.710.42 0.037
Weekly PD Kt/V 1.480.31 1.600.39 1.560.35 1.500.35 0.954
Weekly renal Kt/V 0.500.37 0.360.35 0.360.41 0.210.44 0.028
Total weekly CCr L/week 7430 6124 6429 5011 0.003
Residual GFR mL/min/1.73 m2 2.271.98 1.491.58 1.611.91 0.801.42 0.011
Abbreviations are: EPO, erythropoietin; PD, peritoneal dialysis; Kt/V, urea clearance; CCr, creatinine clearance; GFR, glomerular filtration rate. Continuous values
are expressed as mean  SD.
a Significance for trend effect was tested across the four groups of patients
and LVMi also was not equivalent. The decline in weekly of uremia or reduced total urea and creatinine clearance
secondary to loss of RRF may be responsible for theKt/V and CCr across the four groups of patients with in-
creasing LVMi was associated with significant reduction progressive cardiac hypertrophy observed in long-term
CAPD patients, although the exact uremic toxin causingof RRF but not changes in PD Kt/V. Completely anuric
patients had significantly greater LVMi compared to cardiac hypertrophy needs further determination.
It is important to caution that our study is cross-sec-those with some RRF (GFR between 0 and 2 mL/min/
1.73 m2) despite having comparable weekly Kt/V values tional in nature and the association identified is not cau-
sation. One can argue whether better preservation leadsof over 1.7 by having a higher PD Kt/V value. This sug-
gests that although a lower degree of RRF was associated to a lower tendency towards LVH or whether it is the
reverse, that is, the patient with a more severe LVH orwith a greater LVMi, the compensatory increase in
PDKt/V was not associated with a reduction in the poor cardiac function could be more likely to lose their
RRF, or whether all of these factors are caused by aLVMi. Our current findings together with recent study
showing progressive increase in LVH with worsening of common primary problem such as duration on dialysis
or medication such as ACEI. Also, it is important tocardiac performance in patients maintained on CAPD
for over five years duration [29] suggest that the degree consider the possibility of a “lead time bias,” that is,
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Table 4. Hemodynamic, biochemical and dialytic parameters in relation to the degree of residual renal function in CAPD patients
Glomerular filtration rate mL/min/1.73 m2
0 0 and 2 2 P value
(N  52) (N  63) (N  43) for trenda
Systolic blood pressure mm Hg 15018 14616 14318 0.192
Diastolic blood pressure mm Hg 8410 849 849 0.978
Arterial pulse pressure mm Hg 6614 6212 5914 0.053
Number of antihypertensives 1.61.0 1.61.0 1.60.8 0.982
Hemoglobin g/dL 9.151.43 9.161.55 10.421.59 0.001
On EPO N (%) 36 (69) 23 (37) 9 (21) 0.001
Cumulative 12-month EPO dose 10 3 U 11386 4266 3564 0.001
Serum albumin g/L 27.93.7 29.24.0 30.14.6 0.031
Daily PD exchanges L 7.131.26 6.401.10 6.031.12 0.001
Total weekly Kt/V 1.730.33 1.780.31 2.170.51 0.001
Weekly PD Kt/V 1.730.33 1.540.31 1.330.34 0.001
Residual GFR mL/min/1.73 m2 0 0.960.53 3.641.67 0.001
Total weekly CCr L/week 457 539 8729 0.001
Abbreviations are: EPO, erythropoietin; PD, peritoneal dialysis; Kt/V, urea clearance; CCr, creatinine clearance; GFR, glomerular filtration rate. Continuous values
are expressed as mean  SD.
a Significance for trend effect was tested across the four groups of patients
patients who have had ESRF for a longer duration are remains poorly understood. As hypoalbuminemia is an
important risk factor for LVH [33, 34], this may explainmore likely to have LVH as well as lose their RRF.
Further prospective study is therefore needed to deter- the more severe LVH observed in Chinese PD patients.
The mechanisms whereby the degree of RRF is associ-mine if indeed there is a cause and effect relationship
between RRF and LVH. ated with the severity of LVH are likely multi-factorial.
One possible mechanism may be related to the reducedAn extremely high prevalence of LVH (90%) and
more severe LVH was observed in our population com- EPO production with a decline in residual GFR [35],
as noted by the significant positive correlation betweenpared to that in Caucasians (75%) [4, 5]. However, those
studies combined both HD and PD patients together hemoglobin and GFR. Patients with no RRF were sig-
nificantly more anemic and had a higher requirementand the echocardiographic data were obtained shortly
after initiation of dialysis [4, 5], compared to 42  31 for EPO. Anemia is a well-known cause of LVH in
dialysis patients [36], and correction of anemia with EPOmonths on dialysis for our study patients. An earlier
study of the same group showed that 65% of the HD results in the partial regression of LVH [37]. It is intri-
guing to note that despite the facts that group IV in-and 90% of the PD patients had LVH [30]. The much
higher prevalence of LVH noted in their PD patients in cluded the greatest proportion of patients treated with
EPO and received the highest cumulative EPO dosage,fact was similar to our current results. Long-term CAPD
has been reported to be disadvantageous in preserving they remained the most anemic among all four groups.
Further stratifying patients according to the degree ofcardiac performance and is associated with the greatest
LVMi compared to both short-term CAPD and HD [29]. residual GFR showed that anuric patients not only had
the greatest LVMi, they were also the most anemic de-More recent study also showed that long-term CAPD
patients are more volume expanded and display more spite having the highest EPO requirement and receiving
the highest cumulative EPO dosage. The greater resis-severe LVH than HD patients [31]. This may explain
the higher prevalence and more severe LVH observed tance to the EPO’s action and greater degree of anemia
in anuric patients may be related to inadequate dialysisin our patients. However, it is important to note that
even when compared to long-term Caucasian [5, 31] or secondary to the loss of RRF, since RRF contributes
significantly to the delivery of adequate dialysis.Japanese PD [30] patients, the LVMi of our patients were
still much higher. The exact reason for this difference Residual renal function also may play a role in limiting
the increase of LVMi by improving the overall Kt/V andis uncertain, but may be related in part to the lower
hemoglobin (Hb; 9.4 g/dL) of our patients compared to removal of uremic toxins. This is evident by the increase
of LVMi with a decline in CCr in pre-dialysis chronicsome series (10.6 g/dL) [31] but not others [4, 5]. The
other possibility may be that our patients had more se- renal failure patients [12], and the regression of LVH and
improvement of cardiac function in patients initiatingvere hypoalbuminemia (29 g/L) compared to Caucasian
(34 to 38 g/L) [5, 31] or Japanese PD patients (37 g/L) CAPD [38]. The fact that residual GFR, but not PD
Kt/V, showed a significant association with LVMi, to-[30]. Indeed, previous study already pointed out lower
serum albumin among our Chinese [32] compared to the gether with previous studies showing regression of LVH
post-kidney transplant [13] suggest some non-dialyz-Caucasian PD patients [23], although the exact cause
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Fig. 1. Left ventricular mass index in relation
to the degree of residual glomerular filtration
rate (A; P  0.001), peritoneal dialysis urea
clearance (B; P 0.857) and total weekly urea
clearance (C; P  0.001).
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Table 5. Multiple regression analysis showing important factors associated with left ventricular mass index in peritoneal dialysis patients
Variable Estimated mean P value 95% Confidence Interval Adjusted R2
Body weight kg 2.95 0.001 1.72 to 4.18 0.311
Arterial pulse pressure mm Hg 1.57 0.001 0.66 to 2.48
Hemoglobin g/dL 8.82 0.036 17.06 to 0.57
Serum albumin g/L 5.78 0.001 8.77 to 2.79
Residual glomerular filtration rate mL/min/1.73 m2 7.94 0.031 15.13 to 0.74
Table 6. Echocardiographic parameters in relation to the degree of On the other hand, the independent association noted
residual glomerular filtration rate in CAPD patients
of RRF and LVMi suggests LVMi may be increased via
Glomerular filtration rate mL/min/1.73 m2 other mechanisms. LVH with disproportionate septal
0 0 and 2 2 P value thickening was associated with renin-angiotensin system
(N  52) (N  63) (N  43) for trenda (RAS) activation [40]. Involvement of the RAS indeed
LVMi g/m2 256.799.6 214.080.4 186.668.1 0.001 was evidenced by the regression of LVH with converting
LVeds cm 3.460.86 3.290.72 3.020.74 0.022 enzyme inhibition independent of the hypotensive effectLVedd cm 5.010.88 4.970.75 4.810.68 0.409
in dialysis patients [41]. Renin secretion continues evenIVSd cm 1.570.39 1.400.35 1.390.34 0.020
LVPWd cm 1.450.31 1.290.32 1.200.21 0.001 after disuse atrophy of the kidneys with almost complete
LVEF % 66.412.1 70.29.9 74.99.4 0.001 deterioration of its excretory function [42], and this mayFS % 31.48.3 34.07.3 37.87.7 0.001
serve as an important neurohormonal mediator for pro-Abbreviations are: LVMi, left ventricular mass index; LVeds, left ventricular
end-systolic diameter; LVedd, left ventricular end-diastolic diameter; IVSd, inter- gressive LVH in these patients. Sympathetic overactivity,
ventricular septal end-diastolic thickness; LVPWd, left ventricular posterior wall mediated by the failing kidneys [43], has been demon-thickness in diastole; LVEF, left ventricular ejection fraction; FS, fractional short-
ening. Continuous values are expressed as mean  SD. strated in dialysis patients with left ventricular dysfunc-
a Significance for trend effect was tested across the four groups of patients tion or hypertrophy [44], and may contribute to LVH and
arterial modeling, independent of its hypertensive action
[45, 46]. Whether sympathetic overactivity and RAS acti-
vation are more marked in completely anuric dialysisable uremic toxins may be important in the progression
patients, hence resulting in more severe cardiac hyper-of LVH.
trophy, requires further investigation. Reduction of sym-A recent study demonstrated that arterial pulse pres-
pathetic hyperactivity by enalapril but not amlodipinesure is the most significant blood pressure parameter in
in chronic renal failure patients suggests that convertingpredicting future LVMi and change in LVMi in the gen-
enzyme inhibition eliminates the stimulatory effects oferal population [39]. Our current study also confirms
angiotensin II on the central nervous system [47]. ACEIit to be independently associated with LVH in dialysis
was most frequently used among patients with the great-patients. Moreover, arterial pulse pressure was signifi-
est LVMi (group IV) while use of ACEI was the lowestcantly and positively correlated with GFR. A trend to-
among patients with no LVH (group I). The severe car-ward lower systolic blood pressure was observed among
diac hypertrophy and resulting cardiac dysfunction inpatients with greater RRF. This suggests a better salt
fact may be the reason for the more frequent use ofand water removal among those with greater RRF, and
ACEI in group IV patients. Prospective studies arehence better fluid control and lower LVH and LV dila-
needed to determine if inhibition of the RAS will pre-tion, although total body water would be more accurately
serve RRF and slow down the progression of cardiacassessed using bioelectric impedance.
hypertrophy in dialysis patients.Hypoalbuminemia is associated with progressive LVH,
Diabetic ESRF patients were deliberately not in-LV dilation and cardiac failure in dialysis patients [33, 34].
cluded in this study because a lot of these patients alsoPrevious studies showed an important contribution of
have diabetic cardiomyopathy other than uremic cardio-RRF to the overall nutrition status of dialysis patient
myopathy, and it is difficult to separate the two entities[28]. The significant decline in serum albumin with de-
on a purely clinical ground. Moreover, these patientscrease in GFR across the three groups of patients may
have a higher prevalence of vascular disease and silentbe attributed to inadequate dialysis (Table 4). Moreover,
ischemia, and more severe cardiac hypertrophy accordingserum albumin was reduced significantly across the four
to the study by Foley et al [48]. Hence, in order togroups of patients with increasing LVMi. This suggests
study the association between RRF and LVMi in uremicthat the novel association between the degree of RRF
patients, only non-diabetic ESRF patients were included.and severity of LVH may be mediated in part by hypoal-
In summary, to our knowledge this is the first studybuminemia, the severity of which was increased among
anuric patients with reduced weekly Kt/V. that demonstrates an important and novel association
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ventricular hypertrophy after renal transplantation. Transplanta-between the degree of RRF and severity of LVH in
tion 70:570–575, 2000
ESRF patients undergoing long-term CAPD. Its associa- 14. Sahn DJ, De Maria A, Kisslo J, Weyman A: Committee on
M-mode standardization of the American Society of Echocardiog-tion with LVH appears to be mediated via mechanisms
raphy. Recommendations regarding quantification in M-modethat are both dependent and independent of its relation-
echocardiography: Results of a survey of echocardiographic mea-
ship with other known risk factors for LVH, namely, in- surements. Circulation 58:1072–1083, 1978
15. Schiller NB, Shah PM, Crawford M, et al: Recommendationscreased arterial pulse pressure, anemia and hypoalbumi-
for quantification of the left ventricle by two-dimensional echocar-nemia. Prospective longitudinal studies are needed to
diography. American Society of Echocardiography Committee on
evaluate if a decline in RRF with time on dialysis is in- Standards, Subcommittee on Quantitation of Two-Dimensional
Echocardiograms. J Am Soc Echocardiogr 2:358–367, 1989dependently associated with an increase of LVMi in
16. Krumholz HM, Larson M, Levy D: Prognosis of left ventricularCAPD patients. Our results also demonstrate the need
geometric patterns in the Framingham Heart Study. J Am Coll
to identify more effective treatment to better preserve Cardiol 25:879–884, 1995
17. Van Olden RW, Krediet RT, Struijk DG, Arisz L: MeasurementRRF in dialysis patients. Whether improved preserva-
of residual renal function in patients treated with continuous ambu-tion of RRF will slow down the progression of cardiac
latory peritoneal dialysis. J Am Soc Nephrol 7:745–748, 1996
hypertrophy, improve cardiac performance and hence 18. Nolph KD, Moore HL, Twardowski ZJ, et al: Cross-sectional
assessment of weekly urea and creatinine clearances in patientssurvival of this population requires further determina-
on continuous ambulatory peritoneal dialysis. ASAIO J 38:M139–tion. M142, 1992
19. Mak TW, Cheung CK, Cheung CM, et al: Interference of cre-
atinine measurement in CAPD fluid was dependent on glucoseACKNOWLEDGMENTS
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